Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $550,798.29 in Stock

Key Points

• Daniel Barber, CEO of Aquestive Therapeutics, sold 91,343 shares of the company's stock for approximately $550,798, reducing his ownership stake by 9% but still retaining 923,430 shares valued at over $5.5 million.
• Aquestive Therapeutics' recent stock performance saw a drop to $5.65 after trading down by $0.34 on Monday, with a market cap of $563.42 million and a notable P/E ratio of -8.07.
• Research firms have varying outlooks on the stock, with Zacks upgrading it to "hold" and Oppenheimer raising the price target to $8.00, while overall, analysts maintain a consensus "Buy" rating.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) CEO Daniel Barber sold 91,343 shares of the stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $6.03, for a total value of $550,798.29. Following the sale, the chief executive officer owned 923,430 shares in the company, valued at $5,568,282.90. The trade was a 9.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Daniel Barber also recently made the following trade(s):

• On Friday, September 19th, Daniel Barber sold 400 shares of Aquestive Therapeutics stock. The stock was sold at an average price of $6.00, for a total value of $2,400.00.

Aquestive Therapeutics Stock Performance

Shares of Aquestive Therapeutics stock traded down $0.34 on Monday, reaching $5.65. 3,783,104 shares of the company were exchanged, compared to its average volume of 1,807,882. The company's 50-day moving average is $4.37 and its two-hundred day moving average is $3.50. The firm has a market cap of $563.42 million, a price-to-earnings ratio of -8.07 and a beta of 1.82. Aquestive Therapeutics, Inc. has a 1-year low of $2.12 and a 1-year high of $6.43.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04. The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AQST. Zacks Research upgraded Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 13th. Oppenheimer lifted their target price on Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an "outperform" rating in a report on Monday, September 8th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. Finally, Lifesci Capital upgraded Aquestive Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Aquestive Therapeutics presently has a consensus rating of "Buy" and an average price target of $10.29.

Institutional Trading of Aquestive Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Modern Wealth Management LLC acquired a new stake in shares of Aquestive Therapeutics in the second quarter worth $33,000. BNP Paribas Financial Markets boosted its position in shares of Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock worth $31,000 after buying an additional 4,134 shares during the period. Jane Street Group LLC acquired a new stake in shares of Aquestive Therapeutics in the second quarter worth $217,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Aquestive Therapeutics by 6.0% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company's stock worth $156,000 after buying an additional 2,649 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Aquestive Therapeutics by 16.6% in the second quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company's stock worth $106,000 after buying an additional 4,557 shares during the period. Institutional investors and hedge funds own 32.45% of the company's stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.